Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ARQT with free AI briefings, catalyst countdowns, and dilution alerts.

ARQT · Arcutis Biotherapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$259.5M Cash on Hand
CF+ Cash Runway
15.3% Short Interest
$40.38 Analyst Target (8)
Follow ARQT by email Get an email when ARQT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ARQT, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-02-23 ZORYVE cream 0.05% infants with mild to moderate atopic dermatitis sNDA 89%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What ARQT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Roflumilast
FDA approved Jul 2022 · Zoryve
Atopic Dermatitis Eczema Phase 3 · NCT04804605 Completed
Roflumilast Cream 0.15% ITCH Phase 4 · NCT07560618 Recruiting
Topical roflumilast Chronic Plaque Psoriasis Phase 3 · NCT04286607 Completed
Roflumilast Foam 0.3% Seborrheic Dermatitis Phase 3 · NCT07683806 Recruiting
Roflumilast Foam Seborrheic Dermatitis Phase 3 · NCT04973228 Completed
Roflumilast Cream 0.3% Atopic Dermatitis Phase 3 · NCT07916480 Recruiting
Roflumilast Cream 0.05% Atopic Dermatitis Eczema Phase 3 · NCT04845620 Completed
ARQ-151 0.3% cream Chronic Plaque Psoriasis Phase 3 · NCT04211389 Completed
Roflumilast Cream Atopic Dermatitis Eczema Phase 3 · NCT04773600 Completed
Roflumilast 0.3% cream Chronic Plaque Psoriasis Phase 3 · NCT04211363 Completed
Topical roflumilast 0.3% foam Hidradenitis Suppurativa Phase 2 · NCT07077902 Completed
Roflumilast topical 0.3% foam Non-segmental Vitiligo Phase 2 · NCT07105254 Recruiting
ARQ-252 cream 0.3% Vitiligo Phase 2 · NCT04811131 Terminated
ARQ-252 cream 0.1% Chronic Hand Eczema Phase 1/2 · NCT04378569 Completed
ARQ-154 Seborrheic Dermatitis Phase 2 · NCT04445987 Completed
ARQ-151 cream 0.5% Psoriasis Phase 1/2 · NCT03392168 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ARQT holds $259.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARQT files for a raise →

👥 Who Owns ARQT

Insiders 1.5% Institutions (414 holders) 98.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 17,751,435 14.04% 2026-09-30
Montanova Capital LLC Institution (13F) 12,269,000 9.70% 2026-09-30
Frazier Life Sciences Management, L.P. Institution (13F) 9,874,511 7.81% 2026-09-30
Rubric Capital Management LP Institution (13G, 5%+) 8,271,577 6.54% 2025-12-31
STATE STREET CORPORATION Institution (13G, 5%+) 7,718,628 6.10% 2026-09-30
Polar Capital Holdings Plc Institution (13G, 5%+) 6,606,945 5.22% 2026-06-30
UBS Group AG Institution (13F) 5,533,053 4.38% 2026-09-30
Morgan Stanley Institution (13F) 5,296,532 4.19% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 4,994,043 3.95% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 3,817,697 3.02% 2026-09-30
Todd Watanabe
Reporting Person's title: President and · +266,000 options
Insider 895,140 0.71% 2026-11-02
Christopher Peetz
Director · +13,010 options
Insider 191,815 0.15% 2026-07-15

Share count 126,455,033 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-04
filed 2026-11-04
Matsuda Masaru
Option exercise (M) 40,000 $3.64 151,289
2026-11-04
filed 2026-11-04
Matsuda Masaru
Sale (S) 40,000 $34.32 111,289
2026-11-04
filed 2026-11-04
Matsuda Masaru
Option exercise (M) 40,000 – –
2026-11-02
filed 2026-11-04
Burnett Patrick
Sale (S) 943 $31.86 116,649
2026-11-02
filed 2026-11-04
Watanabe Todd
Sale (S) 4,377 $31.86 712,826

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-10-13 — sNDA +13.3% +3.3% +4.1%

Browse all historical PDUFA outcomes →

Get the full ARQT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARQT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.